INDIANAPOLIS, March 21, 2016 -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices, including the CardioChek® family of analyzers, A1CNow® systems, and PTS Detect™ cotinine systems, announced today that they have signed a national sales and distribution agreement with Anda, an Allergan company. Anda is a national medical distribution company that sells over-the-counter pharmaceutical products to retail independent and chain pharmacies, nursing homes, mail-order pharmacies, hospitals, clinics and physician offices.
“Anda is well positioned with many of the key market segments that PTS Diagnostics’ portfolio of products serves,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We are quite pleased Anda will become our newest distributor in the United States. Given our medical devices’ ability to measure point-of-care results for lipids (cholesterol), A1C, and cotinine as well as the ability to offer many more laboratory tests with a simple fingerstick, we anticipate significant further growth within the pharmacy, clinic and physician office settings.”
Founded in 1992, Anda is the fourth largest supplier of generic pharmaceuticals in the U.S., and is a premier distributor for new-to-market product launches to retail chains. With over 60,000 locations to sell to and 220 sales representatives making 18,000 telephone calls a day, Anda stocks more than 10,000 line items.
“Point-of-care testing is rapidly growing among pharmacies, hospitals, clinics and physician offices,” said Anthony Mihelich, Anda’s Vice President of Purchasing. “PTS Diagnostics CardioChek lipid analyzers, A1CNow+ systems and PTS Detect cotinine systems are prime for expansion within these markets. We stock the latest technologically advanced products that are in high demand with our customers. The PTS Diagnostics portfolio of products fills this market need nicely.”
PTS Diagnostics also offers critical information management functionality with digital capture and transfer of biometric screening information with its PTS Connect solutions. This suite of digital products make connectivity flexible and information management simple. In addition, the PTS Connect wellness solution provides an online account for wellness program participants to view biometric information and monitor ongoing health improvement.
About PTS Diagnostics
PTS Diagnostics is an innovative, global, point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decision. The company’s name represents the three pillars upon which it has built its long-term success: People, Technology and Service. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610 or [email protected].
Tom Wiser 317-517-2216


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Instagram Outage Disrupts Thousands of U.S. Users
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



